{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-25-000057","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2025-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.202577+00:00","generated_at":"2026-05-23T05:01:36.972345+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BeiGene files 2024 STAR annual report; US GAAP revenue $3.81B, gross margin down","bullets":["Revenue $3.81B in 2024, up 55% YoY from $2.46B; gross margin 85.1% vs 84.5% prior year.","China revenue $1.41B (gross margin 62.9%, down from 68.0%); ex-China revenue $2.40B (97.1% vs 98.0%).","Total R&D expenses $1.95B, up 10% YoY; zanubrutinib R&D $129M, tislelizumab $69M, Bcl-2 $100M.","Key product sales 5.0M vials in 2024; inventory 2.6M vials as of Dec 31, 2024.","Differences between PRC GAAP and US GAAP outlined for share-based comp and lease accounting."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-25-000057","json":"https://secwatch.observer/filing/0001651308-25-000057.json","markdown":"https://secwatch.observer/filing/0001651308-25-000057.md","text":"https://secwatch.observer/filing/0001651308-25-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130825000057/0001651308-25-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130825000057/bgne-20250428.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T05:01:36.972345+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}